Search Results

You are looking at 11 - 20 of 398 items for :

  • pharmacokinetics x
Clear All
Open access

Ioana Todor, Dana Muntean, Maria Neag, Corina Bocsan, Anca Buzoianu, Laurian Vlase, Daniel Leucuta, Ana-Maria Gheldiu, Adina Popa and Corina Briciu

References 1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391-99. 2. B Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9. 3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571-90. 4. Findling RL. Evolution

Open access

Alenka Marušič, Igor Locatelli and Aleš Mrhar

-606. Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, et al. Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin-Tazobactam. Pharmacotherapy 2007; 22: 569-77. Božidar V. Farmakoterapijski priručnik (5. izdaja). Medicinska naklada Zagreb, 2007. Posamezni povzetki glavnih značilnosti zdravil (SmPC). V: Baza podatkov o zdravilih. Upravljalec: Javna agencija RS za zdravila in medicinske pripomočke. Pridobljeno 11.12.2009 s spletne strani: http

Open access

Diana Pop, Ana-Maria Gheldiu, Monica Oroian, Adriana Marcovici, Sandeep Bhardwaj, Arshad Khuroo, Ravi Kochhar and Laurian Vlase

, Lewis BC, et al. Identification of the human cytochromes P450 catalyzing the rate-limiting pathways of gliclazide elimination. Br J Clin Pharmacol. 2007;64(4):450-7. 15. Todor I, Muntean D, Neag M, et al. The influence of CYP2D6 phenotype on the pharmacokinetic profile of atomoxetine in Caucasian healthy subjects. Acta Medica Marisiensis. 2017;63(2):73-9. 16. Rojanasthien N, Autsavakitipong T, Kumsorn B, et al. Bioequivalence study of modified-release Gliclazide tablets in healthy volunteers. ISRN Pharmacol. 2012;2012. doi:10.5402/2012/375134. 17

Open access

Małgorzata Gbylik-Sikorska, Anna Gajda, Artur Burmańczuk, Tomasz Grabowski and Andrzej Posyniak

References 1. de Boer V.C., Dihal A.A., van der Woude H., Arts I.C., Wolffram S., Alink G.M., Rietjens I.M., Keijer J., Hollman P.C.: Tissue distribution of quercetin in rats and pigs. J Nutrit 2005, 135, 1718–1725. 2. Chang L., Ren Y., Cao L., Sun Y., Sun Q., Sheng N., Yuan L., Zhi X., Zhang L.: Simultaneous determination and pharmacokinetic study of six flavonoids from Fructus Sophorae extract in rat plasma by LC–MS/MS. J Chrom B 2012, 904, 59–64. 3. Coppin J.P., Xua Y., Chena H., Pan M.H., Hoc Ch.T., Juliani R., Simon J.E., Wu Q

Open access

Stoica Ciprian Mihai, Căldăraru Carmen Denise, Vari Camil Eugen, Tarţa Dorin Ionuţ, Dogaru Maria Titica, Caraşca Emilian and Dogaru Grigore Aloiziu

transplantation. Prilozi 2011;32:87-103. 12. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481–508. 13. Michael F. Crutchlow, Roy D. Bloom. Transplant-associated hyperglycemia: A new look at an old problem.Clin J Am Soc Nephrol 2007;2:343–355. 14. Pirsch J, Bekersky I, Vincenti F et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000;40:527-532. 15. Hasselink DA, Ngyuen H, Wabbijin M et al

Open access

L. Carlucci, K.H. Song, H.I. Yun, H.J. Park, K.W. Seo and M. Giorgi

) Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40: 1399-1418. Fassler PE, Tranquilli WJ, Paul AJ, Soll MD, DiPietro JA, Todd KS (1991) Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin- sensitive Collies. J Am Vet Med Assoc 199: 457-460. Gabrielsson J, Weiner D (2002) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm, Sweden. German AJ (2006) The growing problem of obesity in

Open access

A. Burmańczuk, T. Grabowski, T. Błądek, C. Kowalski and P. Dębiak

Drugs. Cephalosporin Drugs. Extralabel Animal Drug Use. Order of Prohibition 735-744. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295364/ Gibaldi M, Perrier D ( 1982 ) Pharmacokinetics. 2nd ed. Marcel Dekker, New York. Grabowski T, Marczak M, Jaroszewski JJ, Whitmire M ( 2012 ) Comparison of bioequivalence study regulatory requirements for human and veterinary drugs. Regul Toxicol Pharmacol 64: 233-242. Gruet P, Maincent P, Berthelot X, Kaltsatos V ( 2001 ) Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev

Open access

DD Milovanovic, JR Milovanovic, M Radovanovic, I Radosavljevic, S Obradovic, S Jankovic, D Milovanovic and N Djordjevic

Introduction Carbamazepine belongs to the older generation of anticonvulsants, which is almost completely metabolized in the liver through processes that involve several liver enzymes, including CYP2C8 [ 1 - 4 ]. To date, there are 16 different CYP2C8 alleles described http://www.cypalleles.ki.se/cyp2c8.htm ), most of them associated with altered enzyme activity [ 5 ]. Although genes could affect the drug metabolism there is a general lack of evidence of influence of CYP2C8 genetic variations on carbamazepine pharmacokinetics, especially in children [ 6

Open access

H. Ziółkowski, J.J. Jaroszewski, N. Ziółkowska and A. Jasiecka

References Adusumalli VE, Gilchrist JR, Wichmann JK, Kucharczyk N, Sofia RD ( 1992 ) Pharmacokinetics of felbamate in pediatric and adult beagle dogs. Epilepsia 33: 955-960. Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, Sofia RD ( 1991 ) Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab Dispos 19: 1116-1125. Ambrósio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM ( 2001 ) Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of

Open access

S. Yohannes, Md. Akil Hossain, J.Y. Kim, S.J. Lee, D.M. Kwak, J.W. Suh and S.C. Park

References Abo-el-Sooud K, Goudah A (2010) Influence of Pasteurella multocida infection on the pharmacokinetic behavior of marbofloxacin after intravenous and intramuscular administrations in rabbits. J Vet Pharmacol Ther 33: 63-68. Albarellos G, Montoya L, Landoni M (2005) Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats. Vet J 170: 222-229. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance